Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18~* Patient with PBC defined by 2 in 3 of the following criteria Positive antimitochondrial antibody type M2. Abnormal serum alkaline phosphatases (ALP \> 1,5N) and aminotransferase (AST or ALT \> 1N) activities.~Histological hepatic injuries consistent with PBC from biopsy specimens of at least 10 mm.~* Patient treated with UDCA at the dose of 13 to 15 mg/kg/d (consistent to the AMM)~* Patients showing an incomplete biochemical response to UDCA as defined by : ALP \> 1,5N or AST \> 1,5N or total bilirubin \>17 µmol/l (with conjugated bilirubin \> 8 µmol/l) after ≥ 3 months of UDCA at the dose of 13 - 15 mg/kg/day.~Exclusion Criteria:~* Unsigned consent.~* Patient with no social insurance or having medical assistant of state~* Ascites or gastrointestinal bleeding (or history of these)~* Serum total bilirubinemia \> 50 μmols/L (3 mg/dl) (sample \< 3 months)~* Serum albuminemia \< 35 g/l (sample \< 3 months)~* Prothrombin index \< 70% (sample \< 3 months)~* Platelet count \< 100000/mm3 (sample \< 3 months)~* Treatment with corticosteroids, immunosuppressive agents, fibrates (or other PPAR-agonists) or statin in the last 3 months~* Any comorbidity susceptible to cause a hepatic impairment (HBV, HCV, or HIV seropositivity; excessive alcohol consumption; hemochromatosis, Wilson's disease, α1 antitrypsin deficiency; celiac disease; uncontrolled dysthyroidism; autoimmune hepatitis, inflammatory colitis)~* Any severe comorbidity decreasing life expectancy~* Intolerance or hypersensitivity to fibrates, to one of these components or other fibrates in general~* Known photosensitivity reaction to fibrates~* Pregnancy or desire of pregnancy~* Breast-feeding~* Renal failure (clearance of creatinine \< 60 ml/mn)~* Patient with congenital galactosemia, syndrome of glucose malabsorption, lactase deficiency due to the presence of lactose in tablets of bezafibrate 400 mg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bezafibrate (Type: EXPERIMENTAL): 400 mg/Day
- Placebo (Type: PLACEBO_COMPARATOR): 1 tablet/ day

Based on this trial design, predict the completion outcome and termination type (if applicable).